Friday, 5 July - Key studies of the day

SEE WEBCASTS BELOW

SO-009: Phase 1 studies assessing the safety and clinical activity of autologous and allogeneic NKG2D-based CAR-T therapy in metastatic colorectal cancer
Eric Van Cutsem, et al.

The conclusion from authors abstract:

Safety, clinical and translational research data comparing autologous and allogeneic approaches at the end of the dose-escalations will be presented, including any potential difference in terms of cell engraftment. These studies will provide critical information to support the development of CAR-T therapy in solid tumors.

 

O-014: Bevacizumab improves efficacy of trifluridine/tipiracil (TAS-102) in patients with chemorefractory metastatic colorectal cancer (mCRC). A Danish randomized trial
Per Pfeiffer, et al.

The conclusion from authors abstract:

Conclusion
In patients with chemorefractory mCRC, FTD/TPI + bevacizumab demonstrated a significant and clinically relevant improvement in PFS and OS compared with FTD/TPI monotherapy, with a favorable safety profile.

 

O-015: Randomised trial of cetuximab every 2 weeks with FOLFIRI or cetuximab with alternating FOLFIRI/FOLFOX in patients with RAS and BRAF wild type metastatic colorectal cancer: Nordic 8 results
Per Pfeiffer, et al.

The conclusion from authors abstract:

Cetuximab every two weeks with FOLFIRI or alternating FOLFIRI/FOLFOX were well tolerated with high RRs and long PFS and OS, however, Nordic 8 did not meet its primary endpoint and we recommend FOLFIRI + cetuximab every 2 weeks in patients with RAS and BRAF wild type mCRC.

 

  • O-026 - Results of REARRANGE trial: A randomized phase 2 study comparing different dosing approaches for regorafenib (REG) during the first cycle of treatment in patients (pts) with metastatic colorectal cancer (mCRC) – Argilés et al - under embargo until Saturday, 6 July 2019 at 11:00 CEST

 

  • LBA-006 - BEACON CRC: a randomized, 3-Arm, phase 3 study of encorafenib and cetuximab with or without binimetinib vs. choice of either irinotecan or FOLFIRI plus cetuximab in BRAF V600E-Mutant Metastatic Colorectal Cancer- under embargo until Saturday, 6 July 2019 at 11:00 CEST